Patient P-02172
Synthetic patientMETA-24 · Day 178 · 35–44 · M · baseline S02Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S02
- Day 65 SC-12 recommended — Supportive Compound SC-12
- Day 66 Patient declined — Not now
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 78 ME-01 recommended — Monitoring Escalation ME-01
- Day 79 Patient accepted — Started ME-01 in the companion
- Day 80 No meaningful change — GI Support Protocol GI-04
- Day 82 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 72.
Primary contributors, last 14 days
- GI instability+31
- Inflammatory activity+25
- Nutritional resilience-11
- Toxicity+6
- Treatment adherence-3
What helped?
- Supportive Compound SC-12Day 65Declined by patient
- GI Support Protocol GI-04Day 71Result: no meaningful change
- Monitoring Escalation ME-01Day 78Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
64%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 64% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable48 min
worsening · -5.3 vs previous 14 d
Sleep duration
Wearable5 h
stable · -0.2 vs previous 14 d
Energy level
Daily log1.2/10
worsening · -0.2 vs previous 14 d
Steps
Wearable4,420
stable · -161 vs previous 14 d
GI burden
Companion83.8/100
worsening · +9.0 vs previous 14 d
Adherence
Companion41.7 %
stable · -0.8 vs previous 14 d
Sleep quality
Wearable7.2/100
worsening · -2.8 vs previous 14 d
Glucose, CGM daily mean
CGM154 mg/dL
stable · -0.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 23 from the failing basin, 96 from restoration.
Would help
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 81%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 81%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 81%
- More proteinGI -7.3 next day on high-intake days · n 20
Would not help
- GI-04 GI Support Protocolalready tried, no meaningful change
- Keep histamine lowGI +5.2 next day on high-intake days · n 23
- Keep ultra-processed lowGI +5.2 next day on high-intake days · n 20
- Keep fat lowGI +4.9 next day on high-intake days · n 20
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-7.3supporter · 95%
- Histamine load+5.2detractor · 95%
- Ultra-processed food+5.2detractor · 95%
- Dietary fat load+4.9detractor · 95%
- Simple carbohydrates+3.3detractor · 64%
- Caffeine+1.1no signal · 18%
- Alcohol-0.8no signal · 15%
- Insoluble fibre-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 84 and rising
- WearableSleep 5.0 h, below personal baseline
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 77
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 34/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓45
- WearableResting HR 86 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 42 ms
- Sleep
- 5.0 h
- Steps
- 4,398
- Resting HR
- 84 bpm
Daily log: GI score 84, nutritional resilience 26, adherence 42.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02514 | 44% | S05 | ME-01 | improved | 44 |
| P-02571 | 43% | S11 | ME-01 | improved | 43 |
| P-02546 | 42% | S20 | NP-02 | improved | 40 |
| P-02146 | 40% | S14 | ME-01 | improved | 33 |
| P-02372 | 40% | S14 | ME-01 | improved | 53 |
| P-02059 | 37% | S03 | SC-12 | improved | 41 |
| P-02157 | 37% | S14 | ME-01 | improved | 55 |
| P-02320 | 36% | S14 | NP-02 | improved | 50 |
| P-02582 | 36% | S14 | ME-01 | improved | 45 |
| P-02628 | 35% | S14 | SC-12 | improved | 47 |
| P-02297 | 34% | S02 | NP-02 | improved | 49 |
| P-02348 | 34% | S14 | GI-04 | improved | 49 |